compound 1 is air stable6 and can be easily converted to trans-
1,2-diaminocyclopentane. More importantly, 1 allows the step-
wise functionalization of amino groups to generate non-C2-type
chiral ligands or medicinal agents.7
Practical Synthesis of
trans-tert-Butyl-2-aminocyclopentylcarbamate and
Resolution of Enantiomers
Recently, we reported that incorporating trans-1,2-diami-
nocyclopentane into aminoethylglycine peptide nucleic acids
(aegPNAs) significantly increases binding affinity and sequence
specificity to complementary DNA.5 Related to this, we
developed an asymmetric synthetic route to (S,S)-1 relying on
Curtius rearrangement and multistep functional group transfor-
mations.5 The route was only serviceable for initial evaluation
of 1 as a building block. Its long sequence and low yield (10
steps, 10% yield) hindered its further application.
Qun Xu and Daniel H. Appella*
Laboratory of Bioorganic Chemistry, National Institute of
Diabetes and DigestiVe and Kidney Diseases, National Institute
of Health, DHHS, 9000 RockVille Pike, Bethesda,
Maryland 20892
ReceiVed July 6, 2006
Our ongoing interest in design and application of trans-
cyclopentane-constrained PNA prompted us to develop a more
efficient and practical process, which can provide multigram
quantities of both enantiomers of 1.8 We envisioned that a
straightforward approach to prepare such diamines would be
ring-opening of an appropriate aziridine with an azide nucleo-
phile in the presence of a promoter.9 In this way, two amine
groups or its equivalents are installed in one step, thus
circumventing the tedious functional group transformations.
Our synthesis begins with ring opening of tosyl-activated
aziridine 2 (Scheme 1, Table 1), which is readily accessible in
one step from commercially available cyclopentene.10 A litera-
ture search revealed four examples of ring-opening of 2 with
azides.11-14 However, our examination of these methods
revealed that none of them gave satisfactory results, especially
for large-scale (4 mmol scale) synthesis. For instance, attempted
opening of 2 with NaN3 using Oxone in aqueous acetonitrile
failed to provide any ring-opening products.11 The use of ceric
ammonium nitrate (CAN) instead of Oxone led to 15%
convension and 13% yield of 3.12 Similar results were observed
when TMSN3 in DMF was used.13 Fortunately, adding 5%
TBAF to TMSN3 significantly promoted the transformation
(entry 4, 80% conversion, 76% yield).14 However, the operation
requires laborious column chromatography to separate azido
amine product 3 from unreacted 2, which has an Rf value close
to that of 3. Complete conversion was achieved by increasing
the amount of TBAF to 20% (entry 5). If 1 equiv of TBAF is
Optically active trans-tert-butyl-2-aminocyclopentylcarba-
mate (1) has potential utility as a scaffold for chiral ligands
and as a modified backbone unit for peptide nucleic acids
(PNAs). We have developed a short and practical synthesis
of 1 via aziridine opening of tosyl-activated cyclopentene
aziridine 2 and optical resolution of racemic 1 with 10-
camphorsulfonic acid (CSA). The route provides ready access
to multigram quantities of both enantiomers without the need
for chromatography.
Optically active 1,2-diamines are important components of
many biologically active natural products and medicinal agents.1
Bidentate C2-symmetric ligands based on 1,2-diamine function-
ality have also found widespread applications in asymmetric
catalysis.2 For example, chiral salen ligands derived from trans-
1,2-diaminocyclohexane effect remarkable enantioselectivity for
a broad range of transformations.3 In contrast, the use of trans-
1,2-diaminocyclopentane as a chiral scaffold has received less
attention due to the limited availability of both enantiomers.4
In connection with our research on peptide nucleic acids
(PNAs),5 we felt that trans-tert-butyl-2-aminocyclopentylcar-
bamate (1) would be a versatile synthetic precursor and that
resolution of racemic 1 should be feasible. In our experience,
(6) When, exposed to air, 1,2-diamines react slowly with carbon dioxide
to produce carbamic acid derivatives. Berkessel, A.; Schro¨der, M., Sklorz,
C. A.; Tabanella, S.; Vogl, N.; Lex, J.; Neudo¨rfl, J. M. J. Org. Chem. 2004,
69, 3050.
(7) Non-C2-type diamine chiral ligands: (a) Mitchell, J. M.; Finney, N.
S. Tetrahedron Lett. 2000, 41, 8431-8434. (b) Christoffers, J.; Schulze,
Y.; Pickardt, J. Tetrahedron 2001, 57, 1765-1769. (c) Fujii, A.; Hashiguchi,
S.; Uematsu, N.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1996, 118, 2521-
2522. Medicinal agents: (a) Szmuszkovicz, J.; Von Voigtlander, P. F. J.
Med. Chem. 1982, 25, 1125-1126. (b) Cheney, B. V.; Szmuszkovicz, J.;
Lahti, R. A.; Zichi, D. A. J. Med. Chem. 1985, 28, 1853-1864.
(8) Pokorski, J. K.; Nam, J.; Vega, R. A.; Mirkin, C. A.; Appella, D. H.
Chem. Commun. 2005, 2101-2102.
(1) For reviews, see: (a) Lucet, D.; Le, Gall, T.; Mioskowski, C. Angew.
Chem., Int. Ed. 1998, 37, 2580-2627. (b) Kotti, S. R. S. S.; Timmons, C.;
Li, G. Chem. Bio. Drug Des. 2006, 67, 101-114.
(2) Yoon, T. P.; Jacobsen, E. N. Science 2003, 299, 1691-1693.
(3) Larrow, J. F.; Jacobson, E. N. Top. Organomet. Chem. 2004, 6, 123-
152.
(4) (a) Luna, A.; Alfonso, L.; Gotor, V. Org. Lett. 2002, 4, 3627-3629.
(b) Toftlund, H.; Pedersen, E. Acta Chem. Scand. 1972, 26, 4019-4030.
(c) Ongeri, S.; Aitken, D. J.; Husson, H. Synth. Commun. 2000, 30, 2593-
2597. (d) Gouin, S. G.; Gestin, J.; Joly, K.; Loussouran, A.; Reliquet, A.;
Meslin, J. C.; Deniaud, D. Tetrahedron 2002, 58, 1131-1136. (e) Daly,
A. M.; Gilheany, D. G. Tetrahedron: Asymmetry. 2003, 14, 127-137.
(5) (a) Pokorski, J. K.; Witschi, M. A.; Purnell, B. L.; Appella, D. H. J.
Am. Chem. Soc. 2004, 126, 15067-15073. (b) Myers, M. C.; Witschi, M.
A.; Larionova, N. V.; Frank, J. M.; Haynes, R. D.; Hara, T.; Grakowski,
A.; Appella, D. H. Org. Lett. 2003, 5, 2695-2698.
(9) For recent reviews on ring-opening of aziridines with azides, see:
(a) Hu, X. E. Tetrahedron 2004, 60, 2701-2743; (b) Sweeney, J. B. Chem.
Soc. ReV. 2002, 31, 247-258.
(10) Jeong, J. K.; Tao, B.; Sagasser, I.; Henniges, H.; Sharpless, K. B.
J. Am. Chem. Soc. 1998, 120, 6844-6845.
(11) Chandrasekhar, S.; Narsihmulu, C.; Sultana, S. S. Tetrahedron Lett.
2002, 43, 7361-7363.
(12) Sabitha, G.; Babu, R. S.; Reddy, S. K.; Yavad, J. S. Synthesis 2002,
2254-2258.
(13) Wu, J.; Sun, X.; Xia, H. Eur. J. Org. Chem. 2005, 4769-4772.
(14) Wu, J.; Hou, X.; Dai, L. J. Org. Chem. 2000, 65, 1344-1348.
10.1021/jo061409v This article not subject to U.S. Copyright. Published 2006 American Chemical Society
Published on Web 10/06/2006
J. Org. Chem. 2006, 71, 8655-8657 8655